MK-8628

Birabresib · Oncoethix GmbH (subsidiary of Merck & Co.)

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MK-8628, covering 2018-05-17 to 2018-10-01. Get the full timeline:

Most recent: Clinical Trial Update: A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) [Phase 1]

See pricing